Author:
Takada M.,Ishiguro H.,Nagai S.,Ohtani S.,Kawabata H.,Yanagita Y.,Hozumi Y.,Shimizu C.,Takao S.,Sato N.,Kosaka Y.,Sagara Y.,Iwata H.,Ohno S.,Kuroi K.,Masuda N.,Yamashiro H.,Sugimoto M.,Kondo M.,Naito Y.,Sasano H.,Inamoto T.,Morita S.,Toi M.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
2. Costa RB, Kurra G, Greenberg L, Geyer CE (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21(11):2153–2160. doi: 10.1093/annonc/mdq096
3. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243. doi: 10.1002/14651858.CD006243.pub2
4. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97(3):188–194. doi: 10.1093/jnci/dji021
5. Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2:CD005002. doi: 10.1002/14651858.CD005002.pub2